Cookie Consent by Free Privacy Policy Generator Update cookies preferences

All scientific sessions

OESO-SEMPIRE 16th World Conference | Esophagus 2024 | Strasbourg | April 23-26, 2024 | Venue: IRCAD France


<  back to Program at a glance

 

The make up of the sessions (Chairs, co-chairs, discussants, questions, and speakers) will be announced as the program is composed. The  information will appear on the website, as well as in newsletters.

All scientific sessions

 

Session 1: ENT: Laryngopharyngeal Reflux


Wednesday, April 24, 9:00 – 10:30 am
Auditorium Léon Hirsch

ChairsJonathan Bock (USA) – Nikki Johnston (USA)

  1. Is HEMII-pH the gold-standard diagnostic tool for LPR? – Jennifer Aoun (Belgium)
  2. Why does the clinical presentation and treatment response of patients with suspected LPR vary? – Inna Husain (USA) 
  3. How does pepsin cause mucosal damage in the context of weakly or nonacid refluxate? – Tina Samuels (USA) 
  4. What is the status of pepsin inhibitors for the treatment of LPR? – Nikki Johnston (USA)
  5. What is the evidence of surgical fundoplication and Linx system in gastro-esophago-laryngopharyngeal reflux? – Edgar J. Figueredo (USA)
  6. What is the role of the UES in LPR? – David M. Richards (USA)

Session 2: Barrett’s Esophagus – Current State of the Art

Wednesday, April 24, 9:00 – 10:30 am
Auditorium Kagame​

ChairsWayne Phillips (Australia) – Dagmar Kollmann (Austria) – George Triadafilopoulos (USA) – Kenneth J. Vega (USA) – Bruno Zilberstein (Brazil)

  1. Introduction & case presentation – George Triadafilopoulos (USA) – Margaret Zhou (USA)
  2. The current landscape of epidemiology & natural history – Kenneth J. Vega (USA)
  3. How is Barrett’s esophagus defined by pathology around the world?  Qin Huang (USA)
  4. What is the cell of origin for Barrett’s esophagus? – Wayne Phillips (Australia)
  5. What is the current ideal screening strategy for Barrett’s esophagus? – Hiroshi Mashimo (USA)
  6. Which Barrett’s esophagus patients should be ablated & by what technique? – Eun Ji Shin (USA) 
  7. What is the role for surgery in the management of Barrett’s esophagus? – Dagmar Kollmann (Austria)

Session 3: Most important esophageal issues affecting my country


Wednesday, April 24, 9:00 – 10:30 am
Auditorium Lindbergh

ChairsJustin Y. Y. Lee (Malaysia) – Adriana Lazarescu (Canada)
Moderator: Marcelo F. Vela Aquino
 (USA)

What is the most important esophageal issue affecting my country now & in the next 20 years?

  1. Daphne Ang (Singapore)
  2. John O. Clarke (USA)
  3. Luigi Bonavina (Italy)
  4. Serhat Bor (Turkey)
  5. Yves Borbely (Switzerland)
  6. Italo Braghetto (Chile)
  7. Hon Chi Yip (Hong Kong)
  8. Valter N. Felix (Brazil)
  9. Matthew Read (Australia)
  10. Jose M. Remes-Troche (Mexico)
  11. Russell E. White (Kenya)
  12. Rona Marie Lawenko (Philippines)

 

Session 4: Pilot Centers (1)

Wednesday, April 24, 11:00 am – 12:30 pm
Auditorium Léon Hirsch

  1. Robert Giuli (France)
  2. Nikki Johnston (USA) – Jonathan Bock (USA)
  3. Rahul Bharadwaj (Malaysia) demo
  4. Justin Y. Y. Lee (Malaysia)

    New Pilot Centers: (recently onboard)​
  5. Mehnaz Shafi (Houston, MD Anderson)
  6. Yinglian Xiao (Guangzhou, by Zoom)
  7. Yutaka Tokairin (Tokyo) 
     
  8. Claire Thibault  Philippe Schultz, Department of Laryngology and Head & Neck Surgery,
    University Hospital Strasbourg: Management of R-CPD (Retrograde Crico-Pharyngeus Dysfunction)

     
  9. Tutorial on RoboticsPeter Grimminger (Germany)

Session 5: Barrett’s Esophagus – Controversies and Future Directions

Wednesday, April 24, 11:00 am – 12:30 pm
Auditorium Kagame​

ChairsWayne Phillips (Australia) – Dagmar Kollmann (Austria) – George Triadafilopoulos (USA) – Kenneth J. Vega (USA) – Bruno Zilberstein (Brazil)

  1. Why is esophageal cancer on the rise? – David Wang (USA)
     
  2. Personal reflections on anti-reflux surgery: 250 patients & 20 years of follow-up – Bruno Zilberstein (Brazil)
     
  3. Debates: point/counterpoint 
  • a) Should irregular z-lines be routinely biopsied?
  • Pro – William Ravich (USA)
  • Con – Nielsen Fernandez-Becker (USA)
  • b) Should non-dysplastic Barrett’s esophagus patients be offered ablation?
  • Pro – John O. Clarke (USA)
  • Con – Allon Kahn (USA)
  • c) Should all patients with Barrett’s esophagus be treated with high-dose PPI therapy and/or aspirin?
  • Pro – Mark R. Fox (Switzerland)
  • Con – Margaret Zhou (USA)
  • d) Should all patients with nodular Barrett’s esophagus be treated with ESD or is EMR OK?
  • Pro – Shai Friedland (USA)
  • Con – Bryan Sauer (USA)
  • e) Should all patients with Barrett’s esophagus be offered an anti-reflux operation & if so, which one?
  • Pro – Valter Felix (Brazil)
  • Con – Salih Samo (USA)
4. How will we approach Barrett’s esophagus in 20 years?
    Wayne Phillips (Australia) – Dagmar Kollmann (Austria) 

Session 6: Distinguished Abstracts Plenary

Wednesday, April 24, 11:00 am – 12:30 pm
Auditorium Lindbergh

ChairsSuzanne S. Gisbertz (Netherlands) – Afrin N. Kamal (USA) 

  1. Mechanisms by which topical alginates preserve esophageal epithelial barrier function during pepsin-weak acid insult – Pelin Ergun (USA)
  2. A novel antireflux procedure for management of gastroesophageal reflux disease: Clinical outcomes of 28 patients treated in Germany – Moustafa Elshafei (Germany)
  3. Diagnostic Yield for Clinically Relevant Abnormal Esophagogastric Junction Opening on Functional Lumen Imaging Probe (FLIP) at 60 mL and 70 mL Distention of 16-cm Balloon: A Case for Routine Measurement to 70 mL – Ryan Flanagan (USA)
  4. Impact of endoscopic pyloric dilatation on symptom relief in delayed gastric emptying after esophageal resection – use of a novel symptom response questionnaire – Mickael Chevallay (Switzerland)
  5. The tumor microenvironment of esophageal cancer is influenced by clinical parameters and neoadjuvant treatment – Styliani Mantziari (Switzerland)
  6. Unveiling the Link Between Balanced and Plant-Based Diets and Esophageal Cancer: Insights from a Chinese Population-Based Cohort Study – Shanrui Ma (China)
  7. Fibrin sealant for prophylaxis of cervical anastomotic leakage after McKeown esophagectomy for esophageal or esophagogastric junction cancer(PLACE030): A Phase III, Multicenter, Randomized Clinical Trial – Zhichao Li (China)
  8. In silico validation and algorithm development of a novel tool for clinical outcome improvement of Barrett’s Esophagus malignant progression – Joana Cardoso (Portugal)

 

 

Session 7: Oncology: Perioperative strategies in esophageal cancer


Wednesday, April 24, 2:00 – 3:30 pm
Auditorium Léon Hirsch

ChairsMarkus H. Moehler (Germany) – Bruno Zilberstein (Brazil)
Moderators: Suzanne S. Gisbertz (Netherlands) – Franco Roviello (Italy) – Thibaud Koessler (Switzerland)

  1. New insights in esophageal cancer biology – Stacey M. Stein (USA)  
  2. Neoadjuvant or perioperative therapy? FLOT vs. CROSS – Sara De Dosso (Switzerland)
  3. Immunotherapy strategies – Markus H. Moehler (Germany)
  4. Targeted therapy: with or without chemotherapy – Thibaud Koessler (Switzerland)

Sessions 8 and 11: Functional Disorders

Wednesday, April 24, 2:00 – 5:30 pm
Auditorium Kagame​

Hour 1
ChairsC. Prakash Gyawali (USA) – 
Roberto Penagini (Italy) 
Moderators: Edoardo V. Savarino (Italy) – Mark R. Fox (Switzerland) – Walter W. Chan (USA) – Ellen M. Stein (USA) 

Potential important topics to discuss:

  • Physiology, mucosal nerve, and innervation 
  • Mechanisms of esophageal hypersensitivity 
  • Achalasia/EGJOO evaluation vs normal transit dysphagia
  • Overlap between GERD and DGBI of esophagus
  • Perceptive vs transit symptoms
  • Globus sensation
  • Invasive intervention in functional disorders

 

Hour 2 (6 Questions)
ChairsWalter W. Chan (USA)  C. Prakash Gyawali (USA)
Moderators: Marcelo F. Vela Aquino (USA) – Justin C. Y. Wu (Hong Kong)

  1. How do you clinically address belching or lack thereof? – Dan Sadowski (Canada)
  2. When to suspect and confirm the diagnosis of rumination? – Joan W. Chen (USA)
  3. Esophageal chest pain or heartburn: is it reflux or not? – Albis C. Hani de Ardila (Colombia)
  4. When nothing is “wrong” – how to approach normal transit dysphagia? – Daphne Ang (Singapore)
  5. Not all cough is reflux - what to do when reflux is ruled out? – Walter W. Chan (USA)
  6. What to do when achalasia is adequately treated but symptoms persist? – Ellen M. Stein (USA)

 

Hour 3 (6 Questions)
ChairsRoberto Penagini (Italy) – Ellen M. Stein (USA)

Moderators: Justin Y. Y. Lee (Malaysia)  Braden Kuo (USA)

  1. Is acid suppression appropriate for treatment of disorders of gut-brain interaction? – Justin Y. Y. Lee (Malaysia)
  2. How to choose the right neuromodulator for esophageal DGBI? – Braden Kuo (USA)
  3. When talking is better than drugs: what are the roles of cognitive behavioral therapy and hypnosis? – Livia Guadagnoli (Belgium)
  4. Is there a role for cannabinoids in esophageal disorders? – Marcelo F. Vela Aquino (USA)
  5. Pins, needles and clips – when to use acupuncture and vagal nerve stimulation? – Justin C. Y. Wu (Hong Kong)
  6. Can digital apps and virtual reality be leveraged for esophageal disorders, or is it too soon? – Eric D. Shah (USA)

Session 9: Interventional Endoscopy (1)


Wednesday, April 24, 2:00 – 3:30 pm
Auditorium Lindbergh

ChairHiroshi Mashimo (USA)

1) Endoscopic hemostasis 

  1. What are the comparative features of topical glues/sprays/gels and considerations for choosing one over the other? Mihir S. Wagh (USA)
  2. What are the comparative features of clips and stitching devices, and what are the considerations for choosing one over the other? – Roberto Trasolini (Canada)
  3. What are recent advances in management of bleeding varices? Stuart R. Gordon (USA)
  4. Topical versus physical closures – how do they compare? – Eun Ji Shin (USA)
     

2) Leaks, fistulas and perforations

  1. What are comparative features of various clips and stitching devices? – Ashish A. Sharma (USA)
  2. How are various stents used for optimal management? – Jon O. Wee (USA)
  3. What are main considerations for Endovacc procedure? – Russel E. White (Kenya)
  4. Considering all maneuvers, what optimal decision path (evidence-based) should be taken in managing perforations, leaks, and fistulas? – Matthew Read (Australia)
     

3) Esophageal Zenker’s diverticulum

  1. What are optimal studies in diagnosis of Zenker’s diverticulum and guiding therapy? Francis J. Scholz (USA)
  2. What are Z-POEM particular indications, comparative data to surgery – Stuart R. Gordon (USA)
  3. What are known complications of Z-POEM and special considerations – Mihir S. Wagh (USA)
  4. Surgical options and when NOT to perform Z-POEMS – Derrick R. Randall (USA)
     

4) Ablative therapies for esophageal neoplasms: burn, freeze, resect

  1. What are considerations of pathogenesis relevant to ablation of neoplasm in esophageal adenocarcinoma versus squamous cell cancer that influence screening, surveillance and therapy? – Qin Huang (USA)
  2. What are the various thermoablative methods and cryoablative methods for neoplastic tissues and special considerations for choosing one over the other? – Roberto Trasolini (Canada) 
  3. Resections: EAC and SCC what special considerations for choosing one over the other? – Hon-Chi Yip (Hong Kong)
  4. What are promising advanced endoscopic imaging tools in evaluation of neoplasm? – Hiroshi Mashimo (USA)
  5. What are considerations of ablative techniques in reducing recurrence? – Eun Ji Shin (USA)
  6. When to burn, freeze, or resect? – Shai Friedland (USA)

Session 10: Oncology: Oncologic strategies in exceptional cases


Wednesday, April 24, 4:00 – 5:30 pm
Auditorium Léon Hirsch


ChairsMarkus H. Moehler (Germany) – Matthew Read (Australia) – Thibaud Koessler (Switzerland)
Moderators: Suzanne S. Gisbertz (Netherlands) – Franco Roviello (Italy) – Thibaud Koessler (Switzerland)

  1. Optimal protocol for clinical complete responders – Sara De Dosso (Switzerland)
  2. Immunotherapy or targeted therapy for resectable esopahageal cancer – Markus H. Moehler (Germany)
  3. The role of immune therapy in palliative esophageal cancer treatment – Jonas Feilchenfeld (Switzerland)
  4. Optimal protocol for locoregional recurrence
  5. New biomarkers: from bench to bedside – Rupert Langer (Austria)
  6. Wait and see strategy after radiochemotherapy – Suzanne S. Gisbertz (Netherlands)
  7. Optimal surveillance of esopohageal cancer patients – Mickael Chevallay (Switzerland)

 

 

Session 12: Interventional Endoscopy


Wednesday, April 24, 4:00 – 5:30 pm
Auditorium Lindbergh

ChairHiroshi Mashimo (USA)

 

1) Endoscopic management of benign strictures

  1. What are various methods of dilations and considerations for optimized use? – Eric G. Sheu (USA)
  2. What are the optimal endoscopic management of refractory/recurrent stricture – Andrew Chang (USA)
  3. What radiological studies show to help guide management – Peter Pokieser (Austria)
  4. What ablation tool to chose: when and why – Roberto Trasolini (Canada)
     

2) Endoscopic management of malignant obstruction

  1. What imaging evaluations are most helpful prior to endoscopy? – Francis J. Scholz (USA)       
  2. Stents, Dilations, and Ablations: which to choose for optimal management?
  3. Are there differences in durability of endoscopic ablations comparing SCC to EAC? – Hon-Chi Yip (Hong Kong)
  4. Complications of endoscopic therapies and how to manage in setting of esophageal cancer – Michael Mwachiro (Kenya)
     

3) Endoscopic treatments of GERD

  1. What endoscopic treatments are available and how do they compare? – Wai-Kit Lo (USA)
  2. What are the roles of motility studies in optimized choice of endoscopic treatment? – Yan Jiang (USA)
  3. What is the role of endoscopic evaluation in choice of treatment? – Nicole Cherng (USA)
  4. Considerations to opt surgery over endoscopic treatments – Ann DeBord-Smith (USA)

4) Endoscopic treatments of achalasia 

  1. What radiological studies and findings are helpful in guiding mode of treatment? – Frank J. Scholz (USA)
  2. What endoscopic options do we have and critical review of manometry and anatomy in choice of therapy? – Georgios Mavrogenis (Greece)
  3. What is the evidence for and against Botox treatments? – John O. Clarke (USA) 
  4. What endoscopic assessments (careful retroflexion?  FLIP?) can better guide therapy? – Salih Samo (USA)
  5. What are considerations in dealing with return of dysphagia after therapy? – Jon O. Wee (USA)
  6. What is a rational approach to selection of achalasia management – Hiroshi Mashimo (USA)

 

 

Session 13: Young Investigators Research


Thursday, April 25, 9:00 – 10:30 am
Auditorium Léon Hirsch

ChairSheraz Markar (UK)

  1. Surgical quality assurance: moving from clinical trial to real world – Sheraz Markar (UK)
  2. The future of robotic surgery – Maria Bencivenga (Italy)
  3. Role of AI in oesophageal cancer treatment 
  4. Role of AI in benign esophageal diseases – Pierfrancesco Visaggi (Italy)

Session 14: Stenosis Medico-Surgical dilemmas

Thursday, April 25, 09:00 – 10:30 am
Auditorium Kagame​

Part I:

ChairJustin Y. Y. Lee (Malaysia) 
ModeratorsRona Marie Lawenko (Philippines) – Peter Pokieser (Austria)

  1. Characterisation of benign stenoses at all levels from the UES to the LES – Peter Pokieser (Austria)
  2. What is the role of surgery in benign stenosis? – Junaidi Hamidi (Malaysia)
  3. Roles of endoscopy and motility in caustic esophageal stenosis – Justin Y. Y. Lee (Malaysia)
  4. Radiology role in the complications of bariatric surgery including sleeve stenosis and gastric bypass herniations of the gastric pouch – Peter Pokieser (Austria)
  5. What is the preoperative role of motility testing? – Rona Marie Lawenko (Philippines)
  6. What is my approach for Zenker Diverticulum? – Stefano Siboni (Italy)

Discussion

Session 15: Techniques and Tips in Esophageal Practice (1)


Thursday, April 25, 9:00 am – 12:30 pm
Auditorium Lindbergh

I: GERD, Antireflux Surgery, and Esophageal Cancer
ChairsRoger P. Tatum (USA) – Afrin N. Kamal (USA)

  1. The retroflexed endoscope: the Hill flap, cardia, and subtle strictures – Hiroshi Mashimo (USA)
  2. PPIs are no longer working – no problem! Tips on when to use PCABs in medical practice – Adriana Lazarescu (Canada) 
  3. Optimal technique for cTIF – Reginald C. W. Bell (USA) 
  4. Robotic repair in reoperative antireflux surgery—leveraging the advantages of robotic technique over standard laparoscopy – Mickael Chevallay (Switzerland) 
  5. When reflux progresses – how to approach Barrett’s esophagus: Screening and Surveillance – Allon Kahn (USA)
  6. Are you sure it’s reflux? How to approach management of laryngopharyngeal reflux – Walter W. Chan (USA) 
  7. Management of cervical anastomotic leak after transhiatal esopahgectomy – Lorrie A. Langdale (USA)

Session 16: Young Investigators Research


Thursday, April 25, 11:00 am – 12:30 pm
Auditorium Léon Hirsch

ChairSheraz Markar (UK)

  1. Liquid biopsy in oesophageal cancer pathway – Mickael Chevallay (UK)
  2. Cancer survivorship – Jessie A. Elliott (Ireland)
  3. Inhaled fosamprenavir for the treatment of airway reflux – Alexandra Lesnick (USA)  
  4. What trials do we look out for in 2024/2025 – Lana Fourie (Switzerland)

Session 17: Stenosis Medico-Surgical dilemmas

Thursday, April 25, 11:00 am – 12:30 pm
Auditorium Kagame​


Part II: 
ChairJustin Y. Y. Lee (Malaysia) 
ModeratorsHon-Chi Yip (Hong Kong) – Junaidi Hamidi (Malaysia)

  1. Evolution in esophagectomy: How to achieve better outcome via minimally invasive approach? – Edward Cheong Chee Keong (Singapore)
  2. Minimally invasive surgery in the era of multimodality treatment of esophageal cancers – Peter Grimminger (Germany)
  3. Clinical Practice Guidelines for EGJ cancer (Upper GI Oncology Summit 2023): What is the role of endoscopy? Justin Y. Y. Lee (Malaysia) 
  4. How do I perform ESD in pre-malignant stenotic conditions? Tips and Tricks – Hon-Chi Yip (Hong Kong)
  5. How do I manage leakage after esophagectomy? – Christian A. Gutschow (Switzerland)
  6. Optimising nutrition in malignant esophageal stenosis – Junaidi Hamidi (Malaysia)
Discussion

 

 

Session 18: Techniques and Tips in Esophageal Practice (2)



Thursday, April 25, 11:00 am – 12:30 pm
Auditorium Lindbergh

II: Motility and Other Esophageal Problems
ChairsRoger P. Tatum (USA), Afrin N. Kamal (USA)
 
  1. Eosinophilic esophagitis in 2024 – how I approach management in complex disease – Jennifer Horsley Silva (USA) 
  2. How to best use intraoperative EndoFLIP in Heller myotomy and POEM – Jacob R. Moremen (USA)
  3. Transhiatal approach to epiphrenic diverticulum – Renato V. Soares (Brazil)
  4. This twitches too much. Management approach to esophageal spasm and Jackhammer esophagus – Anh D. Nguyen (USA)
  5. Techniques for challenging hiatal repair in paraesophageal hernia – Medhat Y. Fanous (USA)
  6. Use of motility and pH testing for procedure selection before bariatric surgery – Judy Y. Chen-Meekin (USA)
  7. Vomiting or Regurgitation? Use of motility testing to identify rumination syndrome – Daniel Sifrim (UK)

Session 19: Eosinophilic esophagitis – current understanding


Thursday, April 25, 2:00 – 3:30 pm
Auditorium Léon Hirsch


Chairs: Emily McGowan (USA) – Bryan Sauer (USA) – Jennifer L. Horsley-Silva (USA) – Neilsen Fernandez-Becker (USA)

  1. The EoE epidemic: history & epidemiology  Kristle Lynch (USA)
  2. Pathology of EoE: definitions & findings beyond eosinophilia – Paul Swanson (USA
  3. EoE & the allergy diathesis: proposed mechanisms & allergy testing – Emily McGowan (USA) 
  4. Approaches to dietary elimination for treatment of EoE – Nielsen Fernandez-Becker (USA)
  5. Understanding the EoE medical treatment arsenal: topical steroids, dupilumab & novel agents – Jennifer L. Horsley-Silva (USA)
  6. The role of the endoscopist in the management of the EoE patient – Bryan Sauer (USA) 

Session 20: Esophageal Cancer: Squamous Cell Carcinoma


Thursday, April 25, 2:00 – 3:30 pm
Auditorium Kagame​

IntroductionAndrew Chang (USA) – Giovanni de Manzoni (Italy)
ChairsKiran H. Lagisetty (USA)
 – You-Sheng Mao (China) – Philippe Morel (Switzerland) 
Moderators: Russel E. White (Kenya) – Rubens A. A. Sallum (Brazil)

 
  1. Pathologic complete response is an equivalent outcomes metric for patients receiving either neoadjuvant chemotherapy or chemoradiation? 
  2. Active surveillance rather than resection is appropriate for patients with esophageal SCC who demonstrate complete clinical response after completing neoadjuvant therapy? – Kiran H. Lagisetty (USA)
  3. Indications for open esophagectomy? – Arnulf Hölscher (Germany)
  4. Are there still surgical indications for proximal esophageal cancer? Rishindra M. Reddy (USA) 
  5. Technique, indications and results for transcervical esophagectomy – Bastiaan Klarenbeek (Netherlands)
  6. The usefulness of a bilateral trans-cervical pneumomediastinal approach for mediastinoscopic radical esophagectomy – Yutaka Tokairin (Japan)
  7. What is the best way to treat anastomotic leakage: cervical anastomosis? – Jon O. Wee (USA)

Session 21: Update in GI Clinical Pharmacology


Thursday, April 25 – 2:00 – 3:30 pm
Auditorium Lindbergh

ChairsCarmelo Scarpignato (Malta) – C. Prakash Gyawali (USA)

  1. Advances in acid suppression: are P-CABs the new frontier? – Carmelo Scarpignato (Malta)
  2. Prokinetics for upper GI tract: where are we and where are we going? – Braden Kuo (USA)
  3. Esophageal mucosal protection: a new avenue for treatment and prevention of mucosal lesions – Daniel Sifrim (UK)
  4. Visceral analgesics: ho do they work and when should be employed – C. Prakash Gyawali (USA)
  5. Nutraceuticals: do they have a role in esophageal diseases? – David Wang (USA)

Session 22: Eosinophilic esophagitis – debates & discussions

Thursday, April 25, 4:00 – 5:30 pm
Auditorium Léon Hirsch
 
ChairsEmily McGowan (USA) – Bryan Sauer (USA) – Jennifer L. Horsley-Silva (USA) – Neilsen Fernandez-Becker (USA)
 
  1. Do we know the natural history of EoE? – Adriana Lazarescu (Canada)
  2. What is the best initial therapy for the symptomatic EoE patient?
    I. Proton pump inhibitors  Walter W. Chan (USA) 
    II. Dietary elimination 
    – Mark R. Fox (Switzerland) 
    III. Swallowed topical steroids 
    – Brent Hiramoto (USA) 
    IV. Dupilumab 
    – John O. Clarke (USA) 
  3. Are there any non-invasive means to assess inflammation? Edoardo V. Savarino (Italy)
  4. Should all EoE providers be performing FLIP for EoE endoscopies? – Abraham Khan (USA)
  5. Does chronic EoE-related esophageal inflammation increase the risk of cancer? – David Wang (USA) 
  6. How will we treat EoE in 10 years? – Emily McGowan (USA)

Session 23: Esophageal Cancer: Adenocarcinoma


Thursday, April 25, 4:00 – 5:30 pm
Auditorium Kagame​

IntroductionArnulf Hölscher (Germany)
«In memoriam Professor Dr. Jörg Rüdiger Siewert – Vita and SIEWERT classification»
ChairsStefan P. Mönig (Switzerland) – Giovanni de Manzoni (Italy)
Moderators: Arnulf Hölscher (Germany) – Bruno Zilberstein (Brazil) – Edward Cheong Chee Keong (Singapore) – Marc van Berge Hennegouwen (Netherlands) 
 
  1. Decision making in Siewert II Adenocarcinoma: gastrectomy versus esophagectomy? – Stefan P. Mönig (Switzerland)
  2. Is thoracic duct resection indicated in adenocarcinoma of the esophagus? – Paolo Morgagni (Italy)
  3. Lymph node dissection of the upper mediastinum – indicated in all patients? – Paul M. Schneider (Switzerland)
  4. Which is the evidence-based surgical approach: transhiatal, left thoracoabdominal, two-stage transthoracic or three-stage transthoracic for distal esophageal adenocarcinoma? – Andrew Davis (UK)
  5. F Is cT1 still a surgical disease, and in which cases? – Maria Bencivenga (Italy)
  6. What is the best way to treat anastomotic leakage: intrathoracic anastomosis? – Marc van Berge Hennegouwen (Netherlands) 

Session 24: Emerging Innovation, AI, and Digital Technology in Esophagology


Thursday, April 25, 4:00 – 5:30 pm
Auditorium Lindbergh

ChairsEric D. Shah (USA) – Austin L. Chiang (USA)

  1. How do you cross the chasm to adopting new esophageal technologies? – Eric D. Shah (USA)
  2. How do you commercialize your idea into a new technology? – Austin L. Chiang (USA)
  3. Multi-Scale Medical Robotics Center: How can you simulate new surgical esophageal innovations? – Hon Chi Yip (Hong Kong)
  4. How artificial intelligence will revolutionize minimally invasive surgery? – Jacques Marescaux (France)
  5. How do you translate open surgery to new minimally invasive foregut surgery techniques? – Rishindra M. Reddy ​(USA)
  6. What is the next big medical device in esophagus care? – Lee L. Swanström (France)
  7. Is artificial intelligence useful to identify Barrett’s esophagus? 
  8. Can artificial intelligence be leveraged to identify esophageal motility disorders? – Pierfrancesco Visaggi (Italy) 
  9. How can digital apps augment esophageal care delivery? – Kristle L. Lynch (USA)

Session 25: Guest Society – American Foregut Society


Friday, April 26, 9:00 – 10:30 am
Auditorium Léon Hirsch

ChairsJacob R. Moremen (USA) – Abraham Khan (USA)

  1. History of American Foregut Society (AFS) – John C. Lipham (USA)                 
  2. Role of Esophageal Function Testing Post-fundoplication – Reena Chokshi (USA)
  3. Post-Fundoplication Syndromes: Surgical Management – John C. Lipham (USA)   
  4. Post-Myotomy Achalasia: Surveillance and Approach to Persistent Symptoms – Joshua Sloan (USA)
  5. Post-Myotomy Failure: Surgical Management – Jacob R. Moremen (USA)
  6. Discussion

Session 26: Obesity and the Esophagus (1)


Friday, April 26, 9:00 – 10:30 am
Auditorium Kagame​

ChairsRalph Peterli (Switzerland) – Minoa K. Jung (Switzerland)

  1. Metabolic bariatric Surgery: State of the art- choice of procedures and outcomes – Ralph Peterli (Switzerland)
  2. Roux-en-Y gastric bypass in superobese patients: what are the results and are there alternatives? – Styliani Mantziari (Switzerland)
  3. Global Benchmarks in robotic bariatric surgery: what are the quality standards? – Minoa K. Jung (Switzerland)
  4. Metabolic bariatric endoscopy: Current procedures and long-term results? – Silvana Perretta (France)
  5. Early complications after primary bariatric surgery and how to manage them? – Pouya Iranmanesh (Switzerland)

Session 27: ENT: Airway Reflux


Friday, April 26, 9:00 – 10:30 am
Rooms C.L.E.M.


ChairsThomas L. Carroll (USA) – Nikki Johnston (USA)

  1. When should you use PPIs for LPR and when should you not? – Serhat Bor (Turkey)
  2. What is the rate of pepsin saliva positivity in asymptomatic individuals and does multi-sampling help us choose treatment? – Jacqueline Allen (New Zealand)
  3. How do anti-pepsin therapies protect against reflux-mediated damage? – Simon Blaine-Sauer (USA)
  4. What is the aetiologic evidence for reflux in adult and pediatric subglottic stenosis? – Derrick R. Randall (Canada)
  5. What are the interactions between laryngopharyngeal reflux and chronic cough? – Jonathan Bock (USA)
  6. How do we determine when the cause of an LPR symptom is due to other laryngeal pathology? – Thomas L. Carroll (USA)
  7. What has been learned about GERD from the lung transplant world? – Sumeet Mittal (USA)

Session 28: Pilot Centers (2)

Friday, April 26, 11:00 am – 12:30 pm
Auditorium Léon Hirsch

  1. Robert Giuli (France)
  2. Rahul Bharadwaj (Malaysia) with demo

    Candidates:
  3. Silvana Perretta (France) – Strasbourg, IHU
  4. Dirk Domagk – Ingo Herrmann (Germany)  Muenster/Dusseldorf 
  5. Richard Gurski (Brazil) Rio Grande do Sul – (Presentation by Bruno Zilberstein (Brazil))

    Debate: Perspectives for the future – Expansion of the Platform
  6. Russell E. White (Kenya)
  7. Rahul Bharadwaj (Malaysia)
  8. George Triadafilopoulos (USA)

Session 29: Obesity and the Esophagus (2)


Friday, April 26, 11:00 am – 12:30 pm
Auditorium Kagame​

ChairsRalph Peterli (Switzerland) – Minoa K. Jung (Switzerland)

  1. Barrett’s esophagus after bariatric surgery: de novo, worsening or resolution? – Judy Y. Chen-Meekin (USA)
  2. What are the benefits and complications of medical treatment of obesity? – Nayna Lodhia (USA)
  3. Association of Achalasia with Morbid Obesity: what is the best treatment? – Ann DeBord-Smith (USA)
  4. What is the impact of bariatric surgery and weight loss on occurence of esophageal cancer? – Eun Ji Shin (USA)
  5. Morbid obesity and reflux burden: what is the effect of bariatric surgery on GERD and esophageal motility? – Brent Hiramoto (USA)
  6. What investigations after bariatric surgery for upper abdominal pain? – Mark R. Fox (Switzerland)

 

Session 30: EGJOO (Esophago-Gastric Junction Outflow Obstruction) in 2024


Friday, April 26, 11:00 am – 12:30 pm
Rooms C.L.E.M.

ChairsJustin C. Y. Wu (Hong Kong) – Kristle L. Lynch (USA)

  1. Is EGJOO an achalasia spectrum disorder? – Enrique Coss-Adame (Mexico)
  2. How do you identify anatomical EGJOO? – Stefano Siboni (Italy)
  3. What is the role of opioids in EGJOO? – Christopher D. Velez (USA)
  4. How should FLIP be used in suspected EGJOO? – Abraham Khan (USA)
  5. How can HRM provocative maneuvers be leveraged to diagnose EGJOO? – Pierfrancesco Visaggi (Italy)
  6. Is medical management feasible in motor EGJOO? – Kristle L. Lynch (USA)
  7. Is pneumatic dilation useful in EGJOO? – Joshua Sloan (USA)
  8. Which EGJOO patients need a myotomy? – Stefano Siboni (Italy) 
  9. What is the prognosis of EGJOO? – Sravanya Gavini (USA)
  10. EGJOO in 2024: where do we go from here? – C. Prakash Gyawali (USA)

Session 31: Updates in GERD


Friday, April 26, 2:00 – 3:30 pm
Auditorium Léon Hirsch

Session I:
ChairsC. Prakash Gyawali (USA), Adriana Lazarescu (Canada)

  1. Wireless pH monitoring vs catheter-based pH-impedance – which is optimal to evaluate each reflux symptoms? – Daniel Sifrim (UK)
  2. Is ambulatory reflux monitoring needed before anti-reflux surgery if LA grade B esophagitis is found on endoscopy? – Robert B. Yates (USA)
  3. Is non-acid reflux clinically relevant and when should we look for it? – Daniela Jodorkovsy (USA)
  4. SAP and SI – which symptom-reflux association metric(s) on ambulatory reflux monitoring should be used and how? – Kenneth J. Vega (USA)
  5. How reliable and clinically relevant are upright vs supine and proximal reflux metrics on ambulatory reflux monitoring? – Adriana Lazarescu (Canada)
  6. Does endoscopic mucosal impedance have a role in the clinical evaluation of reflux? – Marcelo F. Vela Aquino (USA)
  7. When should MNBI and PSPW be routinely incorporated into reflux testing? – Edoardo V. Savarino (Italy)
  8. Can pepsin be used as a reliable clinical marker for reflux? – Wai-Kit Lo (USA)
  9. How should esophageal motility assessment be used in the evaluation of reflux symptoms? – Amit Patel (USA)
  10. How should reflux be diagnosed in 2024? – C. Prakash Gyawali (USA)

Session 32: State of the Art: Surgery



Friday, April 26, 2:00 – 3:30 pm
Auditorium Kagame
 
ChairsArnulf Hölscher (Germany) – Giovanni de Manzoni (Italy)
Moderators: Luigi Bonavina (Italy) – Yves Borbely (Switzerland) – Stefan P. Mönig (Switzerland) – Suzanne S. Gisbertz (Netherlands)
  1. Surgery for Achalasia – Ines Gockel (Germany)
  2. Surgery for Reflux and Hiatal hernia – Christian A. Gutschow (Switzerland)
  3. DiscussionLuigi Bonavina (Italy) – Yves Borbely (Switzerland)
     
  4. Surgery for Adenocarcinoma of the esophagus – Sallum Rubens (Brazil)
  5. Surgery for squamous cell carcinoma of the esophagus – Simon Y. K. Law (Hong Kong)
  6. DiscussionStefan P. Mönig (Switzerland) – Suzanne S. Gisbertz (Netherlands)

Session 33: Pathology 1


Friday, April 26, 2:00 – 3:30 pm
Auditorium Lindbergh

Esophagitis and Barrett's esophagus
ChairsDhanpat Jain (USA)   Rupert Langer (France) 
 

  1. What is the clinical significance of making a diagnosis of sloughing esophagitis? – Dhanpat Jain (USA) 
  2. What is the clinical significance of making a diagnosis of lymphocytic esophagitis? – Monika Tripathi (Canada) 
  3. What is the clinical significance of making a diagnosis of lichenoid esophagitis? – Maryam K. Pezhouh (Canada) 
  4. What are the similarities and differences between lymphocytic and eosinophilic esophagitis? – Sara Hafezi Bakhtiari (Canada) 
  5. Is there any role of counting eosinophils in EOE patients? – Maryam Pezhouh (USA) 
  6. Is there any significance in reporting sub-epithelial fibrosis on biopsies in EOE patients? – Kevin M. Waters (USA) 
    Q&A
     
  7. Should goblet cells be required for the diagnosis of Barrett's esophagus? – Maha Guindi (USA) 
  8. What is diagnostic and prognostic role of p53 IHC in BE and dysplasia? – Huang Qin (USA) 
  9. What are the common challenges in evaluating margins for dysplasia and cancer in esophageal EMR/ESD? – Deyali Chatterjee (USA) 
  10. What is the current status of AI and ML application in Barrett's esophagus? – Sara Hafezi Bakhtiari (Canada) 
    Q&A

Session 34: Updates in GERD


Friday, April 26, 4:00 – 5:30 pm
Auditorium Léon Hirsch

Session II:
ChairsWalter W. Chan (USA) – Kerry B. Dunbar (USA)

  1. Chronic proton pump inhibitor use is bad for my health – myth or fact? – Lawrence F. Borges (USA)
  2. What is the efficacy of PPI for different typical reflux symptoms? – John O. Clarke (USA)
  3. How effective is acid suppression therapy for cough and pulmonary symptoms? – Walter W. Chan (USA)
  4. Does acid suppression therapy have a role in management of reflux hypersensitivity and functional heartburn? 
  5. Should on-demand acid suppression be used in treatment of reflux symptoms? – Kerry B. Dunbar (USA)
  6. What is the role of GABA agonists in the management of reflux symptoms? – Reena Chokshi (USA)
  7. When should mucosal coating agents be used in reflux management? – Rona Marie Lawenko (Philippines)
  8. How does PCAB compare to PPI in endoscopic reflux healing? – Sravanya Gavini (USA)
  9. Are PCAB better than PPI in reflux symptoms control? – Ellen M. Stein (USA)
  10. What are effective therapies for nocturnal acid breakthrough for patients on twice daily PPI? – Irene Sonu (USA)
  11. When should PCAB be considered? – Jose M. Remes-Troche (Mexico)

Session 35: Minimally Invasive and Robotic Esophageal Surgery


Friday, April 26, 4:00 – 5:30 pm
Auditorium Kagame​
 
ChairsPeter Grimminger (Germany) – Suzanne S. Gisbertz (Netherlands)
Moderators: Simone Giacopuzzi (Italy) – Rubens A. A. Sallum (Brazil) – Sheraz Markar (UK) – Yutaka Tokairin (Japan)
  1. How to define and assess the quality of minimally invasive esophagectomy? – Sheraz Markar (UK)
  2. Minimally invasive approach to Siewert III – Franco Roviello (Italy)
  3. Does adopting a minimally invasive approach to esophageal cancer require the use of robotic surgery? – Simone Giacopuzzi (Italy)
  4. Is there a direct and inseparable link between ERAS and minimally invasive approach in esophageal surgery? – Shaun Preston (UK)
  5. RACE procedure: an option to learn? – Rubens A. A. Sallum (Brazil)
  6. Is there a place for minimal invasive limited resection in esophagogastric junction cancer? – Felix Berlth (Germany)

Session 36: Pathology 2


Friday, April 26, 4:00 – 5:30 pm
Auditorium Lindbergh

Esophageal carcinoma
ChairsDhanpat Jain (USA) – Rupert Langer (France)

  1. Should we routinely test for DNA-MMR/MSI esophageal carcinoma (SCC/Adenocarcinoma)Florence Renaud (France)
  2. Should we routinely test for SMARC4/INI in esophageal carcinomas – Monika Tripathi (Canada)
  3. Should we test for PDL-1 in esopageal carcinoma (SCC/Adenoca) and how to report PDL-1 – Paul E.  Swanson (USA)
  4. What is the status of claudin 18.2 testing in esophageal carcinomaDhanpat Jain (USA)
  5. What are the next diagnostic/prognostic and therapeutic biomarkers for esophageal carcinoma after claudin 18.2 and PD-L1? – Florence Renaud (France)
  6. Any role of reporting "Her2 low" in GEJ adenocarcinomaMaha Guindi (USA)
  7. What is the role of NGS in esophageal carcinoma?Rupert Langer (Austria)
  8. What is upcoming and novel biomarkers for progression in BE and dysplasia?Cathy J. Streutker (Canada)
  9. What is the current status of AI and ML application in the pathologic diagnosis of esophageal carcinomaBastian Dislich (Switzerland)
  10. What is the current status of AI and ML application in assesment of tumor regression post neo-adjuvant treated esophageal carcinomaDeyali Chatterjee (USA)
  11. What is the role of liquid biopsy in esophageal carcinoma?Bastian Dislich (Switzerland)
    Q&A